Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
Implications of the Doha Declaration on the Trips Agreement and Public Health - Health Economics and Drugs Series No. 012
(2002; 56 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentForeword
View the documentAcknowledgements
View the documentAbbreviations and acronyms
View the documentExecutive summary
View the documentIntroduction
View the documentScope
View the documentThe role of TRIPS and IPRs
Open this folder and view contentsPublic health measures
Open this folder and view contentsFlexibility in TRIPS
Open this folder and view contentsMembers with insufficient or no manufacturing capacities
View the documentTransfer of technology to LDCs
View the documentExtension of transitional period for LDCs
View the documentSpecial treatment under TRIPS
View the documentLegal status of the Doha Declaration
View the documentIssues not covered in the Declaration
View the documentConclusions
View the documentAnnex 1 - Doha Declaration on the TRIPS Agreement and Public Health
View the documentAnnex 2 - Levels of development of pharmaceutical industry, by country
View the documentReferences
 

Acknowledgements

This paper has been produced with the support of the Department of Essential Drugs and Medicines Policy (EDM) of the World Health Organization (WHO). An expert consultation organized by the Rockefeller Foundation and WHO/EDM was held on 10 June 2002 in New York. The author wishes to acknowledge the valuable comments and input made by the participants at the expert consultation which included: Nick Drager, WHO/Strategy Unit, Office of the Director-General; Desmond Johns, Joint United Nations Programme on HIV/AIDS; Jim Keon, The Canadian Drug Manufacturers Association; Heinz Klug, University of Wisconsin; Sisule Fredrick Musungu, South Centre; Jonathan D. Quick WHO/EDM; Pedro Roffe, United Nations Conference on Trade and Development; Jorgen Smith, Norwegian Patent Office; Germán Velásquez, WHO/EDM; and Robert Weissman, Essential Information; as well as for the comments made by Robert Howse (University of Michigan) and Adrian Otten (World Trade Organization).

Although participants in the review process brought different perspectives to the table, all reviewers, by consensus, agreed that this paper advanced ideas consistent with the TRIPS Agreement and the Doha Declaration on the TRIPS Agreement and Public Health.

Any views expressed are the views of the author and do not necessarily reflect the views of the World Health Organization or the Rockefeller Foundation. The author, is solely responsible for the opinions expressed herein.

This document has been edited by Robert Weissman.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014